Klamaxin is generally applied across domains where additional symptomatic support is needed. The therapeutic use of Klamaxin is relevant across a range of conditions presenting with acute episodes.

This macrolide antibiotic is commonly used to help with infections in the respiratory tract, such as community-acquired pneumonia, acute bronchitis, and maxillary sinusitis; for uncomplicated skin and soft tissue infections; and for localized issues like acute otitis media. Furthermore, it may be part of symptomatic management in combination therapy for H. pylori associated with duodenal ulcers and is commonly used for managing Disseminated Mycobacterium avium Complex (MAC) in specific patient groups. It is commonly used to help with symptom clusters that may become intense or disruptive.

“The primary therapeutic focus is that it contributes to easing the overall symptom load, which supports patients during episodes of heightened discomfort.”

In scenarios where patients experience heightened discomfort, Klamaxin assists with maintaining functional stability, and it is considered relevant for individuals with penicillin allergies.

---

Quick Fact: Use in Inflammatory Symptom Contexts

Property	Description
Primary Symptom Focus	Symptoms related to physical discomfort, systemic imbalance, and inflammatory states.
Usage Context	Conditions involving acute or disruptive episodes and heightened systemic burden.
Patient Benefit	Provides support that helps ease the overall symptom burden and improves comfort.

---

Regulatory References

1. DailyMed official drug label for Clarithromycin

Eligibility Map: Who Can and Cannot Use Klamaxin — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Approved for adults and children aged 6 months and older.
Populations for whom use is not recommended (if applicable)	Pregnant women unless no suitable alternative is available; Women who are breastfeeding.
Populations for whom use is contraindicated	Patients with known macrolide hypersensitivity or history of clarithromycin-linked hepatic dysfunction.

---

Age-Related Eligibility Rules

• Adults (18+): Approved for use under standard labeled conditions.
• Infants (Under 6 Months): Safety and effectiveness are not established and use is generally not recommended.
• Older Adults (Geriatric): Use is permitted, but caution is necessary due to the higher potential for impaired cardiac or renal function.

---

Condition-Specific Eligibility Rules

• Severe Organ Impairment: Contraindicated in patients with severe hepatic failure combined with renal impairment.
• Cardiovascular Risk: Contraindicated in patients with pre-existing conditions like QT prolongation or ventricular arrhythmia.
• Concomitant Drug Ineligibility: Use is contraindicated if taking specific medications, including simvastatin, lovastatin, cisapride, pimozide, or ergot alkaloids.

---

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording (Examples)
Eligibility severity classification	Contraindicated; Not recommended; Use with caution; Safety and effectiveness not established
Regulatory basis	Official Prescribing Information (e.g., FDA Label, EMA SmPC)
Eligibility-context constraints	Co-administration with specific drugs; Pre-existing hepatic, cardiac, or renal dysfunction; Age less than 6 months

Connection to the overall eligibility profile

Regulatory documents define eligibility by absolute contraindications related to macrolide allergy and specific cardiovascular and drug-interaction risks. Further constraints are set by age limitations for infants and condition-specific restrictions for patients with severe organ impairment, requiring caution or mandatory exclusion from use.

Interaction Map: Interactions with other medicines and products — official regulatory information for Klamaxin

Interaction scope

Classification	Medicinal Product Categories	Mechanistic Basis in Label
Contraindicated	QT-Prolonging Agents, Ergot Alkaloids, Specific Statins	Inhibition of CYP3A4, Additive QT Prolongation
Use with Caution	P-gp Substrates, Other CYP3A4 Substrates, Anticoagulants	Inhibition of P-gp Transport and CYP3A4 Metabolism

Specific interacting medicines (if explicitly listed):

• Contraindicated: Cisapride, Pimozide, Astemizole, Terfenadine, Ergotamine, Dihydroergotamine, Lovastatin, Simvastatin, Oral Midazolam, Lomitapide, Ticagrelor, Ivabradine, Ranolazine.
• Other Interactions Listed: Digoxin, Theophylline, Carbamazepine, Phenytoin, Verapamil, Quinidine, Disopyramide, Ritonavir, Fluconazole, Colchicine.

Timing-based interaction rules (if applicable):

• The extended-release formulation must be taken with food to ensure adequate exposure.
• Therapy with certain statins (e.g., Lovastatin, Simvastatin) must be suspended during the course of Klamaxin treatment if co-administration cannot be completely avoided.

Population-specific interaction notes (if applicable):

• Co-administration with colchicine is contraindicated in patients with renal or hepatic impairment due to increased toxicity risk.

---

Interaction classifications (high-level)	Interaction Severity Classification	Regulatory Basis	Interaction-Context Constraints
Contraindicated	EMA / FDA / Health Canada	Metabolism inhibition (CYP3A4) and combined risk of life-threatening cardiac arrhythmia or toxicity.
Clinically Significant	EMA / FDA / Health Canada	Requires monitoring, dose alteration, or avoidance due to altered drug exposure.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define the product’s interaction profile primarily through its potent effect as an inhibitor of the CYP3A4 metabolic enzyme and the P-glycoprotein transporter. This mechanistic property dictates mandatory contraindications for co-administration with specific drugs whose increased systemic exposure poses severe risks, such as cardiac arrhythmia or myopathy. For many other medicines metabolized by the same pathway, the official labeling imposes requirements for intensive monitoring or dose adjustments to manage the resulting altered drug exposure.

Blocking the Bacterial Protein Synthesis Machinery

Klamaxin acts by initiating a translational blockade through precise non-covalent binding to the 50S ribosomal subunit inside susceptible bacteria. This molecular action targets the 23S ribosomal RNA near the peptide exit tunnel, functionally arresting the translocation process required to build new proteins for cell growth and survival. This primary mechanism results in a bacteriostatic state, preventing the population from multiplying and allowing the host immune system to clear the static bacterial population.

Secondary Modulation of Host Physiology

Beyond its direct antimicrobial effects, Clarithromycin engages a secondary mechanism by influencing the host's inflammatory pathways and immune cell signaling. This involves the modulation of mediators like cytokines and chemokines, influencing the production of inflammatory mediators like cytokines. This mechanism affects the host response, shaping the physiological consequence by affecting inflammatory pathways.

Understanding Mechanistic Constraints

The mechanism is constrained by bacterial resistance processes that directly interfere with its target binding. Specifically, ribosomal methylation alters the 23S rRNA binding site, physically blocking Clarithromycin's access. Other limitations include the activity of efflux pumps, which actively transport the drug out of the bacterial cell, preventing the necessary concentration for 50S subunit saturation and functional inhibition.

How to Use Klamaxin

Klamaxin (Clarithromycin) is administered according to specific, official instructions. These rules define the precise route, form, dose, and frequency to ensure proper administration, following established clinical guidelines.

---

Official Routes and Forms

Klamaxin is primarily administered through the oral route, available as Immediate-Release (IR) tablets, Extended-Release (XL) tablets, and granules for oral suspension. An Intravenous (IV) infusion form is also approved for severely ill patients, typically used for a limited duration before transitioning to oral therapy.

---

Standard Dosing and Frequency

The standard adult oral dose for IR tablets typically ranges from 250 mg to 500 mg and is taken every 12 hours (twice daily). The XL tablets are generally prescribed as 1000 mg total daily dose, taken once daily. For most bacterial infections, the treatment duration is usually between 7 and 14 days.

---

Key Administration Conditions

Administration depends on the formulation:

• XL Tablets: Must be swallowed whole and not crushed, broken, or chewed. They must be taken with food.
• IR Tablets & Suspension: May be administered without regard to food.
• Pediatric Use: Children under 12 years are directed to use the oral suspension.
• Dose Adjustment: For patients with severe kidney impairment (creatinine clearance < 30 mL/min), the total dose must be reduced by one-half.

Research evidence / Overview of studies for Klamaxin

Klamaxin (Clarithromycin) is a prescription medicine that was studied for its role in treating various types of bacterial infections. The evidence base for Klamaxin is derived from regulated clinical research, including controlled trials and comprehensive reviews that were evaluated in its research history. This overview focuses only on what types of studies were conducted and what was observed in the research setting, without providing any medical or therapeutic advice.

---

Evidence for Acute Respiratory and Sinus Infections

The research foundation for Klamaxin's use in acute respiratory conditions, such as Community-Acquired Pneumonia (CAP), Acute Bronchitis, and Maxillary Sinusitis, is built upon Randomized Controlled Trials (RCTs) and comparative clinical trials. These studies were conducted during periods of increased symptom activity and research examined outcomes related to physical discomfort and systemic or functional imbalance. Reports documented measurements of the primary clinical endpoint at early time points and at the completion of treatment (Test of Cure).

What remains uncertain is the full impact of increasing antibiotic resistance on the generalizability of these findings, particularly in cases where the bacteria may resist the antimicrobial agent. Certain comparative data used for regulatory review can have limitations if they excluded specific resistant pathogens in their design.

---

Evidence for Specialized Combination Therapies

Klamaxin was studied for its specific role as a component in combination regimens for treating certain conditions characterized by fluctuating or episodic manifestations, including H. pylori associated with duodenal ulcers and Disseminated Mycobacterium avium Complex (MAC).

For H. pylori, the evidence base includes Systematic Reviews and RCTs that primarily measured achievement of eradication outcomes. More recent reports have documented a progressive decline in the achievement of eradication outcomes globally, which indicates that the patterns of outcome observed with older, standard regimens can vary or decrease. For MAC, studies research examined clinical change and measurements of survival time. Findings indicate that the rate of achieving the primary endpoint generally requires the concomitant use of multiple antimicrobial agents.

Key Studies & References

1. Label: CLARITHROMYCIN tablet, film coated - DailyMed - NIH (Official Indications and Clinical Studies)
2. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents - Mycobacterium avium Complex (MAC)
3. Add-on clarithromycin improves community-acquired pneumonia outcomes (Review of prospective trial data on clinical response and inflammatory markers)

Common questions about Klamaxin (FAQ)

---

Q: What should I do if I miss a dose of Klamaxin?

Official drug information commonly states that if a dose of Klamaxin is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the recommendation is to skip the missed dose and continue with the regular schedule. Regulatory information advises against taking a double dose to compensate for the missed one.

---

Q: Can I take Klamaxin with dairy products or grapefruit juice?

Regulatory documents indicate that there are no significant known interactions between Klamaxin and most common foods or drinks. The extended-release formulation has specific requirements regarding administration with food, which are detailed in the official 'How to Use' section. Grapefruit juice may impact how the active ingredient is absorbed in the stomach, but it is not typically listed as a mandatory interaction concern.

---

Q: What are the risks of taking Klamaxin if I have heart problems?

Official safety information for Klamaxin warns that it is associated with a potential for QT interval prolongation, which can lead to a serious type of irregular heartbeat called ventricular arrhythmia. Official labeling includes precautions for individuals who have pre-existing heart conditions, and the medicine is contraindicated in patients with known QT prolongation. Furthermore, certain long-term studies have suggested a potential increased risk of death in patients with coronary heart disease.

---

Q: How quickly does Klamaxin start working?

According to regulatory pharmacokinetic studies, the active ingredient in Klamaxin is rapidly absorbed after being taken orally, with peak concentrations typically reached within two to three hours. Clinical documentation indicates that an improvement in symptoms may be observed within the first few days of treatment, but individual results may vary.

---

Q: Is it safe to drive after taking this medicine?

Official drug safety documentation advises that Klamaxin may affect alertness or coordination. This is due to potential side effects that could impair mental awareness. Official prescribing information advises that individuals should determine how the medicine affects them before they operate vehicles or engage in activities that require mental alertness.

---

Q: What is the difference between Klamaxin IR and XL tablets?

The difference lies in their design and administration requirements. The IR (Immediate-Release) tablets are formulated for standard absorption. The XL (Extended-Release) tablets are designed to release the medication slowly over time, requiring a different dosing frequency and specific administration conditions related to food. The administration details for each form are found in the 'How to Use' section.

How to Store and Dispose of Klamaxin?

Storage Requirements

Preserve Klamaxin in the original container and follow the storage conditions precisely as stated on the product label. If specific temperature requirements, such as refrigeration or a range like Controlled Room Temperature (15 C to 30 C), are noted, adhere to them to maintain the drug’s stability and effectiveness. Always store the medication in a secure location that is dry and protected from excessive heat, moisture, and light, and out of the reach of children and pets.

Disposal Instructions

The safest and most recommended method for disposing of unused or expired Klamaxin is through a drug take-back program. You can often find authorized collection sites or mail-back programs at local pharmacies or law enforcement facilities. If a take-back program is unavailable, consult the accompanying patient information. Do not flush the medication down the toilet unless it is specifically listed by the FDA as a drug required for immediate flushing due to high accidental exposure risk.